Merrimack halts pancreatic cancer trial

June 25, 2018

Merrimack Pharmaceuticals announced it will discontinue the development of an experimental treatment for pancreatic cancer after the drug failed to meet the main and secondary goals of a mid-stage trial.

The treatment, MM-141, was being studied in addition to standard-of-care treatment for patients with previously untreated metastatic pancreatic cancer. The study did not meet its primary or secondary efficacy endpoints in patients who received MM-141 in combination with nab-paclitaxel and gemcitabine, compared to nab-paclitaxel and gemcitabine alone.

The drugmaker has two promising breast cancer clinical programs, MM-121 and MM-310, with data readouts expected in 2018.

Read the press release